Literature DB >> 15653382

Endogenous bone-marrow-derived stem cells contribute only a small proportion of regenerated myocardium in the acute infarction model.

Shinya Fukuhara1, Shinji Tomita, Takeshi Nakatani, Chikao Yutani, Soichiro Kitamura.   

Abstract

BACKGROUND: Our recent study showed that granulocyte-colony stimulating factor (G-CSF) promoted bone-marrow cells (BMC) to migrate into the infarcted heart and that they differentiated into cardiomyocytes. However, we still do not know to what degree bone-marrow-derived cardiomyocytes contribute to myocardial regeneration after injury. In this study, we verified the proportional contribution of cells from bone marrow (BM) and from non-bone marrow (n-BM) in regenerating neomyocardium after myocardial infarction.
METHODS: Eight C57BL/6 mice were irradiated (900 cGy), and green fluorescent protein (GFP) mouse-derived BMCs (GFP-BMC, 1 x 10(6) cells) were injected. Four weeks later, the left descending coronary artery was ligated. Recombinant human G-CSF (200 microg/kg/day, 8 days) was injected. At 4 weeks after ligation, hearts were fixed for histology. We calculated the proportions of cardiomyocytes derived from BM and n-BM after taking the chimeric rate into consideration.
RESULTS: The chimeric rate was 54.6% +/- 5.9%. At the infarcted border area, the total cell number was 1000.3 +/- 56.5/mm(2), and mobilized BM-derived GFP-BMC was 103.3 +/- 13.1/mm(2). After compensation with the chimeric rate, we found BM-derived troponin I-positive cells at 23.9 +/- 4.1/mm(2), nestin-positive cells at 12.9 +/- 2.6/mm(2), and Ki67-positive cells at 18.3 +/- 2.6/mm(2), respectively. We found significant differences in the contribution of troponin I-(6.7% +/- 1.7% vs 93.3% +/- 1.7%), nestin- (2.4 +/- 0.5 vs 97.6 +/- 0.5), and Ki67-positive (3.9 +/- 1.0 vs 96.1 +/- 1.0) cells derived from BM and n-BM.
CONCLUSIONS: Bone marrow was one of the origins of regenerated cardiomyocytes; however, the contribution of cells from BM was very small compared with those of n-BM origin in the infarction model.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15653382     DOI: 10.1016/j.healun.2003.09.032

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  12 in total

1.  Cathelicidin Related Antimicrobial Peptide (CRAMP) Enhances Bone Marrow Cell Retention and Attenuates Cardiac Dysfunction in a Mouse Model of Myocardial Infarction.

Authors:  Yuri M Klyachkin; Amr Idris; Christopher B Rodell; Himi Tripathi; Shaojing Ye; Prabha Nagareddy; Ahmed Asfour; Erhe Gao; Rahul Annabathula; Mariusz Ratajczak; Jason A Burdick; Ahmed Abdel-Latif
Journal:  Stem Cell Rev Rep       Date:  2018-10       Impact factor: 5.739

Review 2.  Granulocyte colony-stimulating factor for ischemic heart failure: should we use it?

Authors:  Marcelo Perim Baldo; Sérgio Lamêgo Rodrigues; José Geraldo Mill
Journal:  Heart Fail Rev       Date:  2010-11       Impact factor: 4.214

3.  In vitro and in vivo effects of bone marrow stem cells on cardiac structure and function.

Authors:  Meifeng Xu; Ryota Uemura; Ying Dai; Yigang Wang; Zeeshan Pasha; Muhammad Ashraf
Journal:  J Mol Cell Cardiol       Date:  2006-12-20       Impact factor: 5.000

4.  Ubiquitous and uniform in vivo fluorescence in ROSA26-EGFP BAC transgenic mice.

Authors:  Maryann Giel-Moloney; Daniela S Krause; Gang Chen; Richard A Van Etten; Andrew B Leiter
Journal:  Genesis       Date:  2007-02       Impact factor: 2.487

5.  Intra-myocardial delivery of mesenchymal stem cells ameliorates left ventricular and cardiomyocyte contractile dysfunction following myocardial infarction.

Authors:  Qun Li; Subat Turdi; D Paul Thomas; Tianjie Zhou; Jun Ren
Journal:  Toxicol Lett       Date:  2010-03-18       Impact factor: 4.372

6.  Evidence of mobilization of pluripotent stem cells into peripheral blood of patients with myocardial ischemia.

Authors:  Ahmed Abdel-Latif; Ewa K Zuba-Surma; Khaled M Ziada; Magdalena Kucia; Donald A Cohen; Alan M Kaplan; Gary Van Zant; Samy Selim; Susan S Smyth; Mariusz Z Ratajczak
Journal:  Exp Hematol       Date:  2010-08-26       Impact factor: 3.084

7.  Mesenchymal stem cells are recruited to striated muscle by NFAT/IL-4-mediated cell fusion.

Authors:  Manja Schulze; Fikru Belema-Bedada; Antje Technau; Thomas Braun
Journal:  Genes Dev       Date:  2005-08-01       Impact factor: 11.361

8.  Bioactive lipids and cationic antimicrobial peptides as new potential regulators for trafficking of bone marrow-derived stem cells in patients with acute myocardial infarction.

Authors:  Anush V Karapetyan; Yuri M Klyachkin; Samy Selim; Manjula Sunkara; Khaled M Ziada; Donald A Cohen; Ewa K Zuba-Surma; Janina Ratajczak; Susan S Smyth; Mariusz Z Ratajczak; Andrew J Morris; Ahmed Abdel-Latif
Journal:  Stem Cells Dev       Date:  2013-02-19       Impact factor: 3.272

Review 9.  Drugs, gene transfer, signaling factors: a bench to bedside approach to myocardial stem cell therapy.

Authors:  Marton Vertesaljai; Zsolt Piroth; Geza Fontos; Gyorgy Andreka; Gusztav Font; Gergely Szantho; Sandor Lueff; Marienn Reti; Tamas Masszi; Laszlo Ablonczy; Eszter D Juhasz; Tamas Simor; Mark S Turner; Peter Andreka
Journal:  Heart Fail Rev       Date:  2007-08-01       Impact factor: 4.214

Review 10.  A novel role for bioactive lipids in stem cell mobilization during cardiac ischemia: new paradigms in thrombosis: novel mediators and biomarkers.

Authors:  Prabhakara R Nagareddy; Ahmed Asfour; Yuri M Klyachkin; Ahmed Abdel-Latif
Journal:  J Thromb Thrombolysis       Date:  2014-01       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.